<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978262</url>
  </required_header>
  <id_info>
    <org_study_id>CIR 292</org_study_id>
    <secondary_id>200-2012-53664-002</secondary_id>
    <nct_id>NCT01978262</nct_id>
  </id_info>
  <brief_title>Immune and Hormone Response to Influenza Vaccine</brief_title>
  <official_title>A Pilot Study of the Immune Response to Influenza Vaccination and Effect on Reproductive Hormones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot research project is to look at the effect of the inactivated
      influenza vaccine (seasonal flu shot) on early signs of immune or germ-fighting response
      known as cytokines or signal molecules. The investigators also want to see if the timing of
      vaccine administration has any effect on women's reproductive hormones. The investigators
      hypothesis is that influenza vaccine given right before ovulation may change the hormone
      levels usually seen after ovulation. Thi
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, longitudinal study of healthy young women of reproductive age,
      not on hormonal contraception who receive seasonal inactivated influenza vaccine (IIV). The
      women will be followed for one menstrual cycle to measure luteinizing hormone surge,
      estradiol, and progesterone, and then vaccinated with the seasonal inactivated influenza
      vaccine prior to ovulation during a second month. At the investigator's discretion, or if
      there is active circulation of influenza virus in Baltimore, the investigators will vaccinate
      during the first menstrual cycle (prior to ovulation) and then follow for a second menstrual
      cycle for comparison. After vaccination, they will be followed for cytokine and chemokine
      responses as well as changes in the concentrations of steroid hormones. This study will
      evaluate the effect of IIV on inflammatory cytokines and hormonal responses before and after
      ovulation. Each woman will have 13 visits in addition to a screening visit, and will be
      followed for 2 complete menstrual cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Levels of Progesterone After Influenza Vaccination</measure>
    <time_frame>2 months</time_frame>
    <description>To explore whether receipt of IIV during the second week of the menstrual cycle (i.e., the week prior to ovulation) is associated with changes in steroid hormone levels, particularly decreases in progesterone, following ovulation.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Cytokine Effect on Reproductive Hormone Levels</measure>
    <time_frame>2 months</time_frame>
    <description>To explore whether inflammatory cytokine responses to IIV receipt are associated with changes in reproductive and stress hormone levels.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine Responses to Influenza Vaccine</measure>
    <time_frame>2 days</time_frame>
    <description>Identify optimal biomarkers of the inflammatory response after vaccination.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>healthy woman</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All women are to receive the quadrivalent influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Inactivated Influenza Vaccine</intervention_name>
    <description>Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly</description>
    <arm_group_label>healthy woman</arm_group_label>
    <other_name>FluZone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18-39 years of age who are in good health.

          -  Good general health as a result of review of medical history and/or clinical testing
             at the time of screening.

          -  Available for the duration of the trial.

          -  Willingness to participate in the study as evidenced by signing the informed consent
             document.

          -  Willing to be abstinent or to use non-hormonal methods of contraception for the
             duration of the study.

          -  History of normal menstrual cycles (26-35 days in length) for at least 3 months.

          -  Willingness to refrain from routine vaccination (except as administered during study)
             for the duration of the study.

        Exclusion Criteria:

          -  Use of contraceptive pills, patch, injection or other hormonal therapies in the
             preceding 3 months (6 months for DepoProvera)

          -  A history of hypersensitivity, including anaphylaxis to any of the components of IIV
             or to eggs.

          -  Previous receipt of a same season licensed influenza vaccine.

          -  Pregnancy as determined by a positive urine or serum human choriogonadotropin (β-hCG)
             test at any point during the study or in the preceding 3 months.

          -  Currently is lactating or breast-feeding.

          -  Fewer than 3 normal menstrual cycles since conclusion of last pregnancy or last use of
             hormonal birth control.

          -  A history of autoimmune disease, or any other chronic medical condition considered
             clinically significant by the investigator.

          -  History of HIV, Hepatitis C or active Hepatitis B.

          -  Known immunodeficiency syndrome.

          -  History of Guillain-Barré syndrome.

          -  Use of chronic oral or intravenous administration (≥14 days) of immunosuppressive
             doses of steroids, i.e., prednisone &gt;10 mg per day, immunosuppressants or other
             immune-modifying drugs within 30 days of starting this study. (Use of topical, nasal
             or inhaled steroids is permitted)

          -  Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to
             study start or during study.

          -  Receipt of blood or blood-derived products (including immunoglobulin) within 6 months
             prior to study vaccination.

          -  Receipt of another investigational vaccine or drug within 30 days prior to study
             start, or during study.

          -  Ongoing, daily use of analgesics or anti-inflammatory medications, including
             nonsteroidal anti-inflammatories. Occasional use, and use associated with menstrual
             periods is acceptable.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kawsar R Talaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Broder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Immunization Research; Johns Hopkins Bloomberg School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jhsph.edu/research/centers-and-institutes/center-for-immunization-research/</url>
    <description>Center for Immunization Research Website</description>
  </link>
  <link>
    <url>http://hopkinsprojectsave.org</url>
    <description>Click here for information about enrolling in this study</description>
  </link>
  <link>
    <url>http://www.cdc.gov/vaccinesafety/activities/cisa.html</url>
    <description>Centers for Disease Control Clinical Immunization Safety Assessment project website</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <results_first_submitted>August 8, 2018</results_first_submitted>
  <results_first_submitted_qc>September 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2018</results_first_posted>
  <last_update_submitted>December 6, 2018</last_update_submitted>
  <last_update_submitted_qc>December 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <keyword>cytokines</keyword>
  <keyword>hormones</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT01978262/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT01978262/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>103 adult female subjects enrolled and 92 completed study over 3 vaccination seasons from 2013-2017. Each participant served as her own control and followed for 2 months: an Inactivated influenza vaccination (IIV) month and a observation/comparator month.</recruitment_details>
      <pre_assignment_details>Study specific screening occurred prior to enrollment. 180 screens completed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Women</title>
          <description>All women are to receive the quadrivalent influenza vaccine
Seasonal Inactivated Influenza Vaccine: Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Women</title>
          <description>All women are to receive the quadrivalent influenza vaccine
Seasonal Inactivated Influenza Vaccine: Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="19" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Levels of Progesterone After Influenza Vaccination</title>
        <description>To explore whether receipt of IIV during the second week of the menstrual cycle (i.e., the week prior to ovulation) is associated with changes in steroid hormone levels, particularly decreases in progesterone, following ovulation.</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Women (Vaccine)</title>
            <description>All women are to receive the quadrivalent influenza vaccine
Seasonal Inactivated Influenza Vaccine: Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly</description>
          </group>
          <group group_id="O2">
            <title>Healthy Women (Comparator)</title>
            <description>All women are to receive the quadrivalent influenza vaccine
Seasonal Inactivated Influenza Vaccine: Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
Comparator Month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Progesterone After Influenza Vaccination</title>
          <description>To explore whether receipt of IIV during the second week of the menstrual cycle (i.e., the week prior to ovulation) is associated with changes in steroid hormone levels, particularly decreases in progesterone, following ovulation.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progesterone Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.60"/>
                    <measurement group_id="O2" value="0.43" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progesterone Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="1.40"/>
                    <measurement group_id="O2" value="0.59" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progesterone Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" spread="4.42"/>
                    <measurement group_id="O2" value="4.53" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progesterone Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.72" spread="4.59"/>
                    <measurement group_id="O2" value="6.32" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progesterone Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.03"/>
                    <measurement group_id="O2" value="0.92" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cytokine Effect on Reproductive Hormone Levels</title>
        <description>To explore whether inflammatory cytokine responses to IIV receipt are associated with changes in reproductive and stress hormone levels.</description>
        <time_frame>2 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cytokine Responses to Influenza Vaccine</title>
        <description>Identify optimal biomarkers of the inflammatory response after vaccination.</description>
        <time_frame>2 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days after vaccination, up to 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Women</title>
          <description>All women are to receive the quadrivalent influenza vaccine
Seasonal Inactivated Influenza Vaccine: Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Eythema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="72" subjects_affected="62" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kawsar Talaat</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-9627</phone>
      <email>ktalaat@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

